(AGENPARL) - Roma, 21 Marzo 2023(AGENPARL) – WASHINGTON mar 21 marzo 2023 There’s no question that countries with smart public policy frameworks drive critical medical innovation. Existing research, like the U.S. Chamber International IP Index, has proven that countries with effective intellectual property (IP) infrastructure experience greater innovative output and better access to resulting innovations, like vaccines and therapeutics. But how can we demonstrate the impact of bad policy decisions? Look no further than the U.S. Chamber’s new Patient Access Report. Data dive: This new report examines the national biopharmaceutical market for nine Organisation of Economic Co-operation and Development (OECD) economies and assesses the impact of their policies on access to innovative medicines. The research shows how imposing price controls and similar policies deters future innovation and access. Relevant and timely: Most OECD economies widely use strict price controls. Before the
Fonte/Source: https://www.uschamber.com/intellectual-property/is-access-to-the-latest-medications-at-risk-for-americas-patients
